Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial

dc.contributor.authorHerbst, Roy S.
dc.contributor.authorBaas, Paul
dc.contributor.authorKim, Dong-Wan
dc.contributor.authorFelip, Enriqueta
dc.contributor.authorPérez-Gracia, José L.
dc.contributor.authorHan, Ji-YouN.
dc.contributor.authorMolina, Julián
dc.contributor.authorKim, Joo-Hang
dc.contributor.authorDubos Arvis, Catherine
dc.contributor.authorGarrido S., Marcelo
dc.date.accessioned2021-05-13T17:51:15Z
dc.date.available2021-05-13T17:51:15Z
dc.date.issued2016
dc.fuente.origenConveris
dc.identifier.doi10.1016/S0140-6736(15)01281-7
dc.identifier.issn0140-6736
dc.identifier.urihttps://doi.org/10.1016/S0140-6736(15)01281-7
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/58313
dc.issue.numeroNo. 10027
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final1550
dc.pagina.inicio1540
dc.revistaThe Lancetes_ES
dc.rightsacceso restringido
dc.titlePembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled triales_ES
dc.typeartículo
dc.volumenVol. 387
sipa.codpersvinculados7260
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Pembrolizumab versus docetaxel for previously treated.pdf
Size:
3.77 KB
Format:
Adobe Portable Document Format
Description: